Detail Information of Microbiota Influence

General Information of Drug Transporter (DT)
DT ID DTD0010 Transporter Info
Gene Name SLC22A1
Transporter Name Organic cation transporter 1
Gene ID
6580
UniProt ID
O15245
Microbiota Influence of This DT (MBI)

Bacteria: Bacillota

   Genus: Ligilactobacillus

     Ligilactobacillus salivarius 

Microbe Info

Click to Show/Hide the Full List 1 Microbe Influence Related to This Species      

       Microbe Influence 1

 Co-transport of human SLC22A1 substrates/drugs in the health condition [1]

Regulating Factor
OCT-like transport

Detailed Description

 The protein OCT-like transport of Ligilactobacillus salivarius DSM 20555 = ATCC 11741 has been reported to transport similar substrates/drugs of SLC22A1, which affects the distribution of its substrate/drug in vivo.

Bacteria: Campylobacterota

   Genus: Helicobacter

     Helicobacter pylori 

Microbe Info

Click to Show/Hide the Full List 1 Microbe Influence Related to This Species      

       Microbe Influence 1

 Sequestration of human SLC22A1 substrates/drugs in the health condition [2]

Studied Tissue

 Stomach

In Vitro Model

 Human gastric epithelial cells

Detailed Description

 The Helicobacter pylori ATCC 700824 has been reported to sequester the drug L-dopamine, which limits the distribution of the drug in the body and its binding to the drug transporter SLC22A1, thereby affecting the efficacy, safety, or bioavailability of the drug.

Bacteria: Host unspecified microbiota

   Genus: Unknown microbiota

     Host unspecified microbiota 

Click to Show/Hide the Full List 5 Microbe Influence Related to This Species      

       Microbe Influence 1

 Up regulating of SLC22A1 expression in colon cancer condition [3]

Regulating Factor
Chenodeoxycholic acid

Studied Phenotype

 Colon cancer [ICD11: 2B90]

Studied Tissue

 Colon

In Vitro Model

 Human colon adenocarcinoma cells (Caco-2)

Detailed Description

 The metabolite chenodeoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.

       Microbe Influence 2

 Up regulating of SLC22A1 expression in colon cancer condition [3]

Regulating Factor
Deoxycholic acid

Studied Phenotype

 Colon cancer [ICD11: 2B90]

Studied Tissue

 Colon

In Vitro Model

 Human colon adenocarcinoma cells (HT-29)

Detailed Description

 The metabolite deoxycholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.

       Microbe Influence 3

 Up regulating of SLC22A1 expression in the health condition [4] , [5]

Regulating Factor
Lithocholic acid

Regulation Mechanism

 via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2) Transcription Factor Info

Studied Tissue

 Liver

In Vivo Model

 IQI mice

Detailed Description

 The metabolite lithocholic acid generated from the host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.

       Microbe Influence 4

 Up regulating of SLC22A1 expression in diabetes condition [6]

Studied Phenotype

 Diabetes [ICD11: 5A10-5A14]

Studied Tissue

 Liver

In Vivo Model

 Rats

Detailed Description

 The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.

       Microbe Influence 5

 Up regulating of SLC22A1 expression in conventional mice compared with germ-free mice [7]

Studied Phenotype

 Conventional mice compared with germ-free mice [ICD11: N.A]

Studied Tissue

 Duodenum

In Vivo Model

 C57BL/6 mice

Detailed Description

 The host unspecified microbiota has been reported to increase the expression of the drug transporter SLC22A1.
References
1 Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of Lactobacillus: Implications for interkingdom communication within the microbiota-gut-brain axis. PLoS One. 2018 Jan 11;13(1):e0191037.
2 In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?. J Pharm Pharmacol. 2009 Oct;61(10):1303-7.
3 Gut Microbiota-Mediated Bile Acid Transformations Alter the Cellular Response to Multidrug Resistant Transporter Substrates in Vitro: Focus on P-glycoprotein. Mol Pharm. 2018 Dec 3;15(12):5711-5727.
4 Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids. Drug Metab Dispos. 2015 Oct;43(10):1505-21.
5 Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica. 2009 Apr;39(4):323-34.
6 In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats. Life Sci. 2019 Jun 1;226:185-192.
7 RNA-Seq Profiling of Intestinal Expression of Xenobiotic Processing Genes in Germ-Free Mice. Drug Metab Dispos. 2017 Dec;45(12):1225-1238.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.